AI Medical Service Inc. (AIM), a Japan-based startup specialising in diagnostic endoscopic artificial intelligence (AI), has announced a significant milestone by signing a joint research agreement with Stanford University School of Medicine, a renowned medical research institute. This partnership marks AIM as the first Japanese company to collaborate with Stanford Medicine in the field of endoscopic AI.
The primary focus of AIM's research endeavours is centred around obtaining regulatory approval in Japan for its endoscopic AI product, designed specifically to detect early-stage gastric cancer. In conjunction with Stanford Medicine, AIM aims to conduct joint research to assess the applicability and effectiveness of Japanese endoscopic AI in the United States.
Gastric cancer is a major global health concern, ranking as the fourth leading cause of cancer-related deaths worldwide. Each year, approximately 26,000 new cases of gastric cancer are diagnosed in the United States alone.
This form of cancer is particularly significant among Asian communities. To address this concern, Stanford Medicine took the initiative to establish CARE (Stanford Center for Asian Health Research and Education) in 2018. CARE's mission is to enhance health outcomes within Asian communities through increased knowledge dissemination and education.
By teaming up with Stanford Medicine, AIM aims to accelerate its research efforts and contribute to the early detection and treatment of gastric cancer, potentially making a positive impact on patients' lives both in Japan and the United States. The collaboration also underscores the increasing global importance of AI-driven medical advancements in the field of endoscopy and cancer detection.
Click here to read the original news story.